Becton Dickinson's $200M Trading Volume Slumps to 467th in U.S. Equities as Stock Falls 1.95% Amid Diagnostic Partnership Speculation

On September 12, 2025, , , ranking 467th in trading volume across U.S. equities. .

Recent developments highlight mixed market sentiment toward the medical technology giant. A announcement with a European pharmaceutical firm to enhance diagnostic testing capabilities has drawn investor attention. However, the decline in trading volume suggests reduced short-term speculative interest, potentially reflecting caution around near-term guidance. Analysts note the partnership could strengthen BDX’s position in high-growth diagnostic markets but emphasize execution risks remain unaddressed.

To run this back-test rigorously I need to pin down a few practical details: 1. Universe • Do you want the entire U.S. listed equity universe (NYSE + NASDAQ + AMEX), or a narrower set such as the S&P 500 constituents? • If it is “all listed stocks”, please confirm whether OTC securities should be included or excluded. 2. Ranking & execution convention • The usual implementation is: – Rank stocks by that day’s trading volume at the close of Day t. – Enter positions at the close of Day t (or at the next day’s open). – Exit at the close of Day t + 1 (one trading day later). • Which price points would you like me to use for entry and exit (close-to-close, open-to-close, etc.)? 3. Transaction costs / slippage • Should we assume zero trading frictions, or apply a round-trip cost (e.g., 5 bp per side)? 4. Data scope • The test period will start 2022-01-03 (first trading day of 2022) and run through today’s close. • Please confirm that horizon. Once these are confirmed, I can generate the data-retrieval plan, build the daily re-balanced portfolio, and compute the strategy’s return and risk statistics for you.